ANTIFIBROTIC ACTIVITY OF MESNA AGAINST AMIODARONE-ASSOCIATED LUNG INJURY IN WISTAR RATS
DOI:
https://doi.org/10.22159/ajpcr.2019.v12i1.30368Keywords:
Pulmonary fibrosis, Amiodarone, MesnaAbstract
Objective: Lung fibrosis is a progressive respiratory disease with a high percentage of mortality. Till now, it had bad prognosis to conventional medications. This study was designed to evaluate the role of mesna, the well-known antioxidant agent, against pulmonary fibrosis.
Methods: Pulmonary fibrosis was induced by administration of amiodarone to Wistar rats. Lung indices, leukocytes count, oxidative stress markers, cytokines levels, and hydroxyproline contents, in addition to the histopathological tests, were done for control, amiodarone, and mesna plus amiodarone group.
Results: The elevated ratio of lung/body weight and total leukocytes count within bronchoalveolar lavage fluid for amiodarone rats was decline significantly when cotreated with mesna therapy. Furthermore, mesna significantly brought down the lipid peroxidation of amiodarone in lung tissue, represented by decreasing malondialdehyde level and increasing superoxide dismutase (SOD) and catalase activity. In addition, mesna diminished the profibrotic transforming growth factor-β1 level while elevated the antifibrotic interferon-γ level, and the high activity of the enzyme matrix metalloproteinase-7 was restored within mesna group. Meanwhile, mesna counteracts the increment of hydroxyproline contents and Ashcroft grading scale within amiodarone group. Histologically, critical improvement in the inflammatory cell penetration and alveolar septa was seen in the lung tissue of rats within mesna group, contrasted with those received just amiodarone. Trichome staining clarified that collagen deposition was notably diminished in the peri-alveolar and peri-bronchial area within mesna group. Moreover, mesna therapy downregulated SMAD3 protein level, which was overexpressed by amiodarone challenge.
Conclusion: This study gives evidence that mesna therapy may act as a protective agent against amiodarone-mediated pulmonary fibrosis.
Downloads
References
Kim DS. Acute exacerbations in patients with idiopathic pulmonary fibrosis. Respir Res 2013;14:86.
Maher TM. Idiopathic pulmonary fibrosis: Pathobiology of novel approaches to treatment. Clin Chest Med 2012;33:69-83.
Gill J, Heel RC, Fitton A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992;43:69-110.
Reinhart PG, Gairola CG. Amiodarone-induced pulmonary toxicity in Fischer rats: Release of tumor necrosis factor alpha and transforming growth factor beta by pulmonary alveolar macrophages. J Toxicol Environ Health 1997;52:353-65.
Chung WH, Bennett BM, Racz WJ, Brien JF, Massey TE. Induction of c-jun and TGF-beta 1 in Fischer 344 rats during amiodarone-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2001;281:L1180-8.
Mashiach E, Sela S, Weinstein T, Cohen HI, Shasha SM, Kristal B, et al. Mesna: A novel renoprotective antioxidant in ischaemic acute renal failure. Nephrol Dial Transplant 2001;16:542-51.
Gressier B, Lebegue N, Brunet C, Luyckx M, Dine T, Cazin M, et al. Scavenging of reactive oxygen species by letosteine, a molecule with two blocked-SH groups. Comparison with free-SH drugs. Pharm World Sci 1995;17:76-80.
Gressier B, Cabanis A, Lebegue S, Brunet C, Dine T, Luyckx M, et al. Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: Comparison in vitro of some thiol- containing drugs. Methods Find Exp Clin Pharmacol 1994;16:9-13.
Walters DM, Wills-Karp M, Mitzner W. Assessment of cellular profile and lung function with repeated bronchoalveolar lavage in individual mice. Physiol Genomics 2000;2:29-36.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-8.
Kakkar P, Das B, Viswanathan PN. A modified spectrophotometric assay of superoxide dismutase. Indian J Biochem Biophys 1984;21:130-2.
Luck H. A spectrophotometric method for the estimation of catalase. In: Bergmeyer HU, editor. Methods of Enzymatic Analysis. New York, USA: Academic Press; 1963. p. 886-7.
Grassi L, Roberge CJ, Frobert Y. Determination of IL-α, IL-β, and IL-2 in biological media using specific enzyme immunometric assays. Immunol Rev 1991;119:125-42.
Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89.
Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor-beta, and S-100 protein in patients with acute stroke. Stroke 1996;27:1553-7.
Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004;4:617-29.
Edwards CA, O’Brien WD Jr. Modified assay for determination of hydroxyproline in a tissue hydrolyzate. Clin Chim Acta 1980;104:161-7.
Maynard JH. A trichrome stain in glycol methacrylate that works. Lab Med 1986;17:471.
Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-70.
Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M, et al. TGF-beta and SMAD3 signaling link inflammation to chronic fibrogenesis. J Immunol 2005;175:5390-5.
Zhou XM, Zhang GC, Li JX, Hou J. Inhibitory effects of hu-qi-yin on the bleomycin-induced pulmonary fibrosis in rats. J Ethnopharmacol 2007;111:255-64.
Soumyakrishnan S, Sudhandiran G. Daidzein attenuates inflammation and exhibits antifibrotic effect against bleomycin-induced pulmonary fibrosis in Wistar rats. Biomed Prev Nutr 2011;1 Suppl 4:236-44.
Wei X, Han J, Chen ZZ, Qi BW, Wang GC, Ma YH, et al. A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res Commun 2010;397:311-7.
Sriram N, Kalayarasan S, Sudhandiran G. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through nrf2- keap1 signaling. Pulm Pharmacol Ther 2009;22:221-36.
Gong LK, Li XH, Wang H, Zhang L, Chen FP, Cai Y, et al. Effect of feitai on bleomycin-induced pulmonary fibrosis in rats. J Ethnopharmacol 2005;96:537-44.
Liang X, Tian Q, Wei Z, Liu F, Chen J, Zhao Y, et al. Effect of feining on bleomycin-induced pulmonary injuries in rats. J Ethnopharmacol 2011;134:971-6.
Grande NR, Peao MN, DeSa CM, Aguas AP. Lung fibrosis induced by bleomycin: Structural changes and overview of recent advances. Scanning Microscope 1998;12:487-94.
Sogut S, Ozyurt H, Armutcu F, Kart L, Iraz M, Akyol O, et al. Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats. Eur J Pharmacol 2004;494:213-20.
Taylor MD, Van Dyke K, Bowman LL, Miles PR, Hubbs AF, Mason RJ, et al. A characterization of amiodarone-induced pulmonary toxicity in F344 rats and identification of surfactant protein-D as a potential biomarker for the development of the toxicity. Toxicol Appl Pharmacol 2000;167:182-90.
Lord-Fontaine S, Averill DA. Enhancement of cytotoxicity of hydrogen peroxide by hyperthermia in Chinese hamster ovary cells: Role of antioxidant defenses. Arch Biochem Biophys 1999;363:283-95.
Siu LL, Moore MJ. Use of mesna to prevent ifosfamide-induced urotoxicity. Support Care Cancer 1998;6:144-54.
Alabbassi MG. The possible protective effects of zileuton against pulmonary fibrosis induced by amiodarone in male rats. J Nat Sci Res 2015;5 Suppl 2:88-92.
Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12:99-106.
Prechtl S, Roellinghoff M, Scheper R, Cole SP, Deeley RG, Lohoff M, et al. The multidrug resistance protein 1: A functionally important activation marker for murine th1 cells. J Immunol 2000;164:754-61.
Yang D, Elner SG, Bian ZM, Till GO, Petty HR, Elner VM, et al. Pro-inflammatory cytokines increase reactive oxygen species through mitochondria and NADPH oxidase in cultured RPE cells. Exp Eye Res 2007;85:462-72.
Lo YY, Wong JM, Cruz TF. Reactive oxygen species mediate cytokine activation of c-jun NH2-terminal kinases. J Biol Chem 1996;271:15703-7.
Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001;107:1529-36.
Scheule RK, Perkins RC, Hamilton R, Holian A. Bleomycin stimulation of cytokine secretion by the human alveolar macrophage. Am J Physiol 1992;262:L386-91.
Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-92.
Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: The myofibroblast in focus. Chest 2007;132:1311-21.
Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, et al. Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol 2008;40:484-95.
de Gouville AC, Huet S. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect 2006;19:85-90.
Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999;341:1264-9.
Yoon JS, Chae MK, Jang SY, Lee SY, Lee EJ. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of graves’ orbitopathy. Invest Ophthalmol Vis Sci 2012;53:5921-9.
Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, Lokshin AE, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5:e93.
Pardo A, Selman M. Role of matrix metaloproteases in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2012;5:S9.
Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002;99:6292-7.
Punithavathi D, Venkatesan N, Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 2000;131:169-72.
Arslan SO, Zerin M, Vural H, Coskun A. The effect of melatonin on bleomycin-induced pulmonary fibrosis in rats. J Pineal Res 2002;32:21-5.
Hübner RH, Gitter W, El Mokhtari NE, Mathiak M, Both M, Bolte H, et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 2008;44:507-11, 514-7.
Oury TD, Thakker K, Menache M, Chang LY, Crapo JD, Day BJ, et al. Attenuation of bleomycin-induced pulmonary fibrosis by a catalytic antioxidant metalloporphyrin. Am J Respir Cell Mol Biol 2001;25:164-9.
Daba MH, Abdel-Aziz AA, Moustafa AM, Al-Majed AA, Al- Shabanah OA, El-Kashef HA, et al. Effects of L-carnitine and ginkgo biloba extract (EG b 761) in experimental bleomycin-induced lung fibrosis. Pharmacol Res 2002;45:461-7.
Zhao J, Shi W, Wang YL, Chen H, Bringas P Jr., Datto MB, et al. SMAD3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002;282:L585-93.
Pardo A, Ruiz V, Arreola JL, RamÃrez R, Cisneros-Lira J, Gaxiola M, et al. Bleomycin-induced pulmonary fibrosis is attenuated in gamma-glutamyl transpeptidase-deficient mice. Am J Respir Crit Care Med 2003;167:925-32.
Serrano-Mollar A, Closa D, Prats N, Blesa S, Martinez-Losa M, Cortijo J, et al. In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. Br J Pharmacol 2003;138:1037-48.
Sushma RK, Sreedhara RP, Nayak JK, Hemalatha B, Keerthana P, Kumar MB. Biomechanical, biochemical and histological evidences for wound healing properties of Indian traditional medicines. Int J Pharm Pharm Sci 2015;7 Suppl 11:163-71.
Iman HH, Mohamed AE, Ghada MA, Walaa GH. Protective effects of Zingiber officinale against carbon tetrachloride induced liver fibrosis. Int J Pharm Pharm Sci 2016;8 Suppl 3:377-81.
Massaous J, Hata A. TGF-beta signalling through the SMAD pathway. Trends Cell Biol 1997;7:187-92.
Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
